PA8429301A1 - Biarilacetilenos como inhibidores de la metaloproteasa de matriz. - Google Patents

Biarilacetilenos como inhibidores de la metaloproteasa de matriz.

Info

Publication number
PA8429301A1
PA8429301A1 PA19978429301A PA8429301A PA8429301A1 PA 8429301 A1 PA8429301 A1 PA 8429301A1 PA 19978429301 A PA19978429301 A PA 19978429301A PA 8429301 A PA8429301 A PA 8429301A PA 8429301 A1 PA8429301 A1 PA 8429301A1
Authority
PA
Panama
Prior art keywords
compounds
disorders
disease
pharmaceutical compositions
diseases
Prior art date
Application number
PA19978429301A
Other languages
English (en)
Spanish (es)
Inventor
Jinshan Chen
Brian R Dixon
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PA8429301A1 publication Critical patent/PA8429301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
PA19978429301A 1996-05-15 1997-05-12 Biarilacetilenos como inhibidores de la metaloproteasa de matriz. PA8429301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502896A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
PA8429301A1 true PA8429301A1 (es) 2000-05-24

Family

ID=24587368

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19978429301A PA8429301A1 (es) 1996-05-15 1997-05-12 Biarilacetilenos como inhibidores de la metaloproteasa de matriz.

Country Status (18)

Country Link
EP (1) EP0912496A1 (fr)
JP (1) JP3090957B2 (fr)
CN (1) CN1139570C (fr)
AR (1) AR007097A1 (fr)
AU (1) AU710759B2 (fr)
BR (1) BR9709077A (fr)
CA (1) CA2253796C (fr)
CO (1) CO5080759A1 (fr)
HN (1) HN1997000088A (fr)
HR (1) HRP970245B1 (fr)
ID (1) ID16910A (fr)
PA (1) PA8429301A1 (fr)
SV (1) SV1997000035A (fr)
TN (1) TNSN97084A1 (fr)
TW (1) TW381079B (fr)
WO (1) WO1997043245A1 (fr)
YU (1) YU18697A (fr)
ZA (1) ZA974031B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AR035478A1 (es) * 1999-01-27 2004-06-02 Wyeth Corp Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1031349A1 (fr) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Utilisation d'acides 4-biarylbutyriques et 5-biarylpentanoiques substitués pour traiter les maladies cérébrales
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CA2804918C (fr) 2010-07-08 2018-03-06 Kaken Pharmaceutical Co., Ltd. Derive de n-hydroxyformamide et produit pharmaceutique le contenant
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
CA2944614A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques a disubstitution 2,5 pour traiter des maladies des voies respiratoires
EP3126339A1 (fr) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2253796A1 (fr) 1997-11-20
CN1139570C (zh) 2004-02-25
CN1225623A (zh) 1999-08-11
HRP970245B1 (en) 2002-06-30
ID16910A (id) 1997-11-20
CO5080759A1 (es) 2001-09-25
WO1997043245A1 (fr) 1997-11-20
HRP970245A2 (en) 1998-04-30
SV1997000035A (es) 1999-01-14
BR9709077A (pt) 1999-08-03
EP0912496A1 (fr) 1999-05-06
HN1997000088A (es) 1997-06-18
JPH11511179A (ja) 1999-09-28
AU710759B2 (en) 1999-09-30
AU2938697A (en) 1997-12-05
ZA974031B (en) 1998-02-19
AR007097A1 (es) 1999-10-13
YU18697A (en) 1999-11-22
TW381079B (en) 2000-02-01
CA2253796C (fr) 2003-10-28
TNSN97084A1 (fr) 2005-03-15
JP3090957B2 (ja) 2000-09-25

Similar Documents

Publication Publication Date Title
PA8429701A1 (es) Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos
PA8429301A1 (es) Biarilacetilenos como inhibidores de la metaloproteasa de matriz.
PA8456801A1 (es) Derivados de acidos ariloxiarilsulfonilamino hidroxamicos
CN109152933A (zh) 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
AR014261A1 (es) Compuestos hipolipidemicos de benzotiazepina, composiciones y proceso para su preparacion
AR007640A1 (es) DERIVADOS DE FENILALANINA, PROCEDIMIENTO PARA PREPARARLOS, PREPARACIONES FARMACEUTICAS QUE LOS CONTIENEN Y EMPLEO DE LOS MISMOS PARA PREPARAR UNMEDICAMENTO QUE ACTUA COMO INHIBIDOR DE LA INTEGRINA ALFA(v)
ES2062943B1 (es) Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
BR9811779A (pt) Tetrahidro prostaglandina s substituìdas por c16-c20 aromáticos úteis como agonistas fp
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
AR003473A1 (es) Uso de la l-carnitina o una acil l-carnitina en donde el acilo es seleccionado del grupo que comprende acetilo, propionilo, butirilo, valerilo e isovalerilo, o de una sal farmacologicamente aceptable de las mismas para la produccion de un medicamento
PA8429801A1 (es) Inhibicion de las metaloproteasas de matriz por compuestos de fenetilo sustituido
ID28365A (id) Turunan produk alami yang baru
PA8429401A1 (es) Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
BR9814913A (pt) Nova substância kf-1040 e processo para produção da mesma
AR002246A1 (es) Nuevas sales por adicion de acidos de cefem procedimientos para su preparacion, el empleo de las mismas para la preparacion de medicamentos, y elprocedimiento para la preparacion de dicho medicamento.
PA8429601A1 (es) Inhibicion de las metaloproteinasas de matriz por acidos 2-(w-aroilalquil)-4-biaril-4-oxobutiricos.
NO844889L (no) Oksicam-derivater og fremgangsmaate til deres fremstilling
ECSP972114A (es) Biarilacetilenos como inhibidores de la metaloproteasa de matriz
AR248406A1 (es) 4-sulfonilamino-2-azinil-1, 2, 4-triazol-3-onas substituidas, procedimiento asi como productos intermediarios para su obtencion y su empleo como herbicidas.
ECSP972111A (es) Inhibidores de la metaloproteinasas de matriz por acidos 2-(aroilalquil)-4 biaril-4- oxobutiricos
PA8510601A1 (es) Eteres de dicarboxilato de calcio, metodos para su preparacion y tratamiento de las enfermedades vasculares y diabetes con los mismos
Follis Jr A survey of bone disease
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
Pastor et al. Cytotoxicity and mitotic alterations induced by non-genotoxic lithium salts in CHO cells in vitro